Try our beta test site
68 studies found for:    Open Studies | "Epstein-Barr Virus Infections"
Show Display Options
Rank Status Study
21 Recruiting Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
Conditions: B-Cell Non-Hodgkin Lymphoma;   Chemotherapy-Related Nausea and/or Vomiting;   Childhood Acute Myeloid Leukemia;   Childhood Burkitt Lymphoma;   Childhood Neoplasm;   Febrile Neutropenia;   Hematopoietic Cell Transplantation Recipient;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Other: Informational Intervention;   Other: Interview;   Other: Medical Chart Review
22 Recruiting Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
Intervention: Biological: CART-19
23 Recruiting Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia
Conditions: Refractory B-cell Acute Lymphoblastic Leukemia;   Relapsed B-cell Acute Lymphoblastic Leukemia
Intervention: Genetic: UCART19
24 Recruiting Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
Conditions: HIV Infection;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Plasmablastic Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Follicular Lymphoma;   Stage III Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Biological: Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation
25 Recruiting A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Protein Expression in Diffuse Large B-Cell Lymphoma
Conditions: Lymphoma, Large B-Cell, Diffuse;   Burkitt Lymphoma
Intervention: Radiation: Gallium citrate
26 Recruiting Dose Escalation Study to Evaluate the Safety, Tolerability and Biological Activity of a Single Dose of UCART19 in Patients With Relapsed / Refractory (R/R) B-cell Acute Lymphoblastic Leukaemia (ALL) and Chronic Lymphocytic Leukaemia (CLL)
Conditions: Acute Lymphoblastic Leukaemia;   Chronic Lymphocytic Leukaemia
Intervention: Genetic: UCART19
27 Recruiting PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
Conditions: Acute Myelogenous Leukemia;   B-cell Acute Lymphoblastic Leukemia;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Chronic Myeloid Leukemia, Blast Crisis
Intervention: Biological: XmAb14045
28 Recruiting A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Condition: B-cell Acute Lymphoblastic Leukemia
Interventions: Drug: Ruxolitinib;   Drug: Asparaginase Erwinia Chrysanthemi;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
29 Not yet recruiting UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Conditions: Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia/Lymphoma;   Burkitt's Lymphoma;   Natural Killer Cell Malignancies;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Large-cell Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-cell Lymphoma;   Prolymphocytic Leukemia;   Bone Marrow Failure Syndromes;   Myeloproliferative Syndromes
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: MMF;   Drug: Sirolimus;   Radiation: TBI;   Biological: Umbilical cord blood cell infusion;   Biological: ATG
30 Not yet recruiting Microbiology of Severe Acute Tonsillitis, Peritonsillar Cellulitis, and Infectious Mononucleosis
Conditions: Acute Tonsillitis;   Peritonsillar Cellulitis;   Infectious Mononucleosis
Intervention: Other: Throat swabbing
31 Recruiting A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas
Conditions: Diffuse Large B-cell Lymphoma;   Follicular Lymphoma;   Burkitt Lymphoma
Intervention: Drug: Alisertib
32 Recruiting Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
Conditions: Non-Hodgkin Lymphoma;   Burkitt's Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular;   Lymphoma, Mantle-Cell;   Lymphoma, Marginal Zone;   Waldenstrom Macroglobulinemia
Intervention: Drug: ADCT-402
33 Recruiting Allo HSCT Using RIC for Hematological Diseases
Conditions: Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Myeloproliferative Syndromes;   Hematological Diseases
Interventions: Drug: Allopurinol;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: ATG;   Radiation: TBI;   Drug: Tacrolimus;   Drug: MMF;   Biological: Peripheral Blood Stem Cells;   Biological: Related or Unrelated Bone Marrow Cells
34 Recruiting Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   Adult T-Cell Leukemia/Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   B Lymphoblastic Leukemia/Lymphoma;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Burkitt Leukemia;   Central Nervous System Lymphoma;   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Diffuse Large B-Cell Lymphoma;   Enteropathy-Associated T-Cell Lymphoma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3 Follicular Lymphoma;   Hepatosplenic T-Cell Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle Cell Lymphoma;   Mediastinal (Thymic) Large B-Cell Lymphoma;   Mycosis Fungoides;   Nasal Type Extranodal NK/T-Cell Lymphoma;   Nodal Marginal Zone Lymphoma;   Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Post-Transplant Lymphoproliferative Disorder;   Primary Cutaneous Anaplastic Large Cell Lymphoma;   Primary Effusion Lymphoma;   Sezary Syndrome;   Splenic Marginal Zone Lymphoma;   Subcutaneous Panniculitis-Like T-Cell Lymphoma;   Systemic Anaplastic Large Cell Lymphoma;   T Lymphoblastic Leukemia/Lymphoma;   Transformed Recurrent Non-Hodgkin Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Dietary Supplement: Salvia hispanica Seed
35 Recruiting Multicenter Trial Treatment of Philadelphia Chromosome Negative B-cell Acute Lymphoblastic Leukemia of Young Adults
Condition: Philadelphia Chromosome Negative Adult B-cell Acute Lymphoblastic Leukemia
Intervention:
36 Recruiting To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma, Burkitt's
Intervention: Drug: Tenofovir
37 Recruiting Lenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma;   CD19 Positive;   Mediastinal Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma
Interventions: Biological: Blinatumomab;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
38 Recruiting Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies
Conditions: Adult Burkitt Lymphoma;   Adult Diffuse Large B-Cell Lymphoma;   CD20-Positive Neoplastic Cells Present;   Indolent Adult Non-Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Refractory Mature B-Cell Non-Hodgkin Lymphoma
Interventions: Biological: Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Clearing Agent;   Drug: Cytarabine;   Drug: Etoposide;   Radiation: Indium In 111-DOTA-Biotin;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Radiation: Yttrium Y 90-DOTA-Biotin
39 Not yet recruiting Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Conditions: Adult Burkitt Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   Diffuse Large B-Cell Lymphoma;   MYC Gene Mutation;   Plasmablastic Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Prednisone;   Biological: Rituximab;   Drug: Therapeutic Hydrocortisone;   Drug: Vincristine Sulfate
40 Recruiting CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies
Conditions: Acute Lymphoblastic Leukemia;   Burkitt Lymphoma
Interventions: Procedure: Leukapheresis;   Drug: Lymphodepletion with fludarabine;   Drug: Lymphodepletion with cyclophosphamide;   Biological: CD19 CAR T-cells

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.